Uncategorized

Drug Quality and Dispensing – Part I

Physicians evaluating medication dispensing from their office often ask about the origin of the pharmaceuticals we distribute.  What they are really asking is “how do I know that you are selling me safe and effective pharmaceuticals?”  The first source to validate pharmaceuticals is the FDA.  The Orange Book is published annually by the FDA and is essentially a list of all pharmaceuticals evaluated by the FDA for safety and effectiveness.  For generics, the products should be rated AA, AB, AN, AO, AP or AT.  This indicates that they are considered therapeutically equivalent to the original brand product; therapeutic equivalence means the following:

  1. They are approved as safe and effective;
  2. They are pharmaceutical equivalents in that they
    1. (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and
    2. (b) meet compendial or other applicable standards of strength, quality, purity, and identity;
  3. They are bioequivalent in that
    1. (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable in vitro standard, or
    2. (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard;
  4. They are adequately labeled;
  5. They are manufactured in compliance with Current Good Manufacturing Practice regulations.

PCA Pharmaceuticals only distributes products rated in the Orange Book in the categories above.  Providers of medication dispensing solutions should be held accountable to distributing FDA approved products.  My next post will talk about some other things to look for when confirming quality and safety of pharmaceuticals.

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading